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httpThe fate of untreated concomitant suprarenal aortic
aneurysms after endovascular aneurysm repair of
infrarenal aortic aneurysms
Benjamin J. Herdrich, MD, Erin H. Murphy, MD, Grace J. Wang, MD, Benjamin M. Jackson, MD,
Ronald M. Fairman, MD, and Edward Y. Woo, MD, Philadelphia, Pa
Objective:Many patients treated with endovascular aortic repair (EVAR) have a concomitant suprarenal abdominal aortic
aneurysm (sAAA). The natural history of these sAAAs and whether they require intervention after EVAR is unknown.
Methods: We identiﬁed 470 patients from the M2S database (M2S Inc, West Lebanon, NH) as having an infrarenal AAA
(iAAA) with a concomitant sAAA (diameter, 2.9-4.7 cm). The analysis included 217 patients with preoperative computed
tomography angiography and follow-up imaging of $12 months. Patients who did not undergo EVAR (n[ 65) served
as a control. Patients with EVAR were subdivided into 90 with suprarenal ﬁxation (SR) and 62 with infrarenal ﬁxation
(IR). Standard measurements from the M2S images were extracted, and growth rates were calculated for different
abdominal aortic segments.
Results: The average follow-up was 33.0 6 18.8 months. The average sAAA initial size and growth rate were 34.6 6 3.0
and 0.6 6 1.1 mm/y for SR, 34.0 6 3.3 and 0.6 6 1.3 mm/y for IR, and 36.6 6 3.4 and 1.2 6 1.5 mm/y for controls
(SR vs IR, P > .05; SR or IR vs control, P < .05). After EVAR, two of 152 (1.3%) sAAAs grew to $50 mm, which
was not statistically different from four of 65 (6.2%) in the control group (P [ .07). At 48 months, the Kaplan-Meier
freedom from sAAA growth to $50 mm was 99.3% for patients undergoing EVAR and 95.2% for controls (P [
.061). Patients with starting sAAAs sized $40 mm had a higher growth rate (1.4 6 2.1 mm/y) and frequency of growth
to $50 mm (14.3%) than patients with starting sAAAs sized <40 mm (0.7 6 1.2 mm/y and 1.5%; P < .05).
Conclusions: Isolated treatment of iAAAs via EVAR with a concomitant sAAA is acceptable because endografts with or
without SR do not affect sAAA growth rates. Routine EVAR follow-up is sufﬁcient for sAAAs of <40 mm, and more
intensive follow-up should be considered for sAAAs of 40 to 50 mm. For sAAAs approaching 50 mm, an endograft with
IR should be considered in case sAAA repair is required in the future. (J Vasc Surg 2013;58:1201-7.)Endovascular aortic repair (EVAR) has become the
standard treatment for infrarenal abdominal aortic aneu-
rysms (iAAAs) when the anatomy is favorable. However,
patients with AAAs may have multifocal disease >10% of
the time.1 Some patients with large iAAAs can have a small
concomitant suprarenal AAA (sAAA), and due to an
absence of reports on the fate of these sAAAs after
EVAR, the best approach to treating these patients is not
known. Speciﬁcally, it is not known whether the sAAA
will continue to dilate and require repair and whether
EVAR might contribute to this process. In these patients,
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://dx.doi.org/10.1016/j.jvs.2013.05.009at the same time when the iAAA becomes large enough
to justify surgery? Should the iAAA be treated alone,
with close monitoring of the sAAA?
A more aggressive approach treating all foci of aneu-
rysmal disease would subject the patient to signiﬁcant oper-
ative risks, and whether small sAAAs need any treatment at
all is not clear unless they increase in size. We hypothesized
that treatment of an iAAA with EVAR in the presence of
a concomitant sAAA sized <50 mm would not affect the
growth of the sAAA. We used the M2S database, which
allowed us to obtain serial aortic measurements from a large
number of patients from multiple institutions. We demon-
strate the fate of concomitant sAAAs after EVAR to treat
large iAAAs and compare that with patients who did not
undergo EVAR.
METHODS
The study included the 470 patients in the M2S Inc
(West Lebanon, NH) database who were identiﬁed as
having an iAAA with a concomitant sAAA sized 3 to
5 cm. To be included in the analysis, patients had to
have preoperative computed tomography angiography
(CTA) and $12 months of follow-up (n ¼ 217). Patients
were excluded for inadequate follow-up time, incomplete
data, or evidence of open surgery. Patients who did not
have an EVAR served as a control (n ¼ 65) group. Those
who had undergone EVAR were further subdivided into1201
Fig 1. Overall study design. CTA, Computed tomography angiography; EVAR, endovascular aortic repair;
f/u, follow-up; iAAA, infrarenal abdominal aortic aneurysm; sAAA, suprarenal abdominal aortic aneurysm.
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infrarenal ﬁxation (IR; Fig 1).
Standard measurements, performed by M2S Inc, were
obtained and analyzed for all patients included in the study.
The measurements used included maximum suprarenal
diameter, maximum infrarenal diameter, iAAA volume,
diameter at the renal arteries, infrarenal neck length, distal
renal artery-to-aortic bifurcation length, proximal neck-to-
iAAA angle, and sAAA-to-proximal neck angle. All diame-
ters were taken as the maximum diameter measured
orthogonal to the centerline in the deﬁned region of the
aorta. The suprarenal aorta was considered from the supe-
rior renal artery to the celiac artery. From these measure-
ments, sAAA growth rate, iAAA growth rate, iAAA
volume growth rate, and growth rate at the renal arteries
were calculated by plotting size or volume (x-axis) vs
time (y-axis) and determining the slope of a best-ﬁt line
for each individual patient.
To look at growth of the sAAA, we identiﬁed all
patients whose sAAAs grew to a size of $50 mm during
the course of the study vs those patients whose sAAAs
remained <50 mm during the study. A size of 50 mm
was chosen as a cutoff because it is considered the smallest
justiﬁable size criteria for treating an sAAA in a patient with
an acceptable surgical risk. Therefore, this would identify
all patients with an operative indication for sAAA interven-
tion regardless of whether the patient was treated. A
Kaplan-Meier survival curve for freedom from sAAA
growth to a size of $50 mm was created for SR and IR
patients undergoing EVAR and for controls, and the log-
rank test was used to determine survival differences among
the groups. Data were analyzed using SPSS 15.0 software
(SPSS Inc, Chicago, Ill).Statistical analysis comparing sAAA growth rate
between sAAAs of <40 and $40 mm was done with
a Mann-Whitney test. Statistical analysis comparing
frequencies of sAAA growth to a size of $50 mm was
done with a Fisher exact probability test. Statistical analysis
comparing aortic measurements and growth rates for SR,
IR, and control groups was done with the Kruskal-Wallis
test for k ¼ 3. When differences among the groups were
identiﬁed, the critical difference of the mean ranks after
Schaich and Hamerle was used to identify which groups
were statistically different from each other at P < .05. All
tests used P < .05 to denote statistical signiﬁcance.
RESULTS
Initial aortic measurements. Initial aortic measure-
ments were taken from the initial CTA and are presented
in Table I. The control group had a larger mean sAAA
(36.6 6 3.4 mm; P < .05) at entry into the study than the
SR (34.6 6 3.0 mm) or the IR (34.0 6 3.3 mm) groups,
which were not signiﬁcantly different. The control group
also had a smaller mean iAAA size (35.2 6 9.9 mm; P <
.05) and iAAA volume (72.66 43.1 mL; P < .05) than the
SR (60.1 6 4.4 mm and 209.3 6 116.3 mL) or IR
(54.6 6 9.5 mm and 150.6 6 55.8 mL) groups, as would
be expected. The iAAAs were larger in the SR group than
in the IR group. Although the difference in iAAA diameter
did not reach statistical signiﬁcance, the SR volume was
signiﬁcantly larger by 39% (P < .05).
The average infrarenal neck length was 18.6 6
11.8 mm for the SR group, 21.5 6 14.5 mm for the IR
group, and 22.6 6 14.4 mm for the control group. The
diameter at the renal arteries was slightly smaller in the
IR group (26.2 6 3.2 mm; P < .05) than in the control
Table I. Initial aortic measurements in patients with infrarenal abdominal aortic aneurysms (iAAAs) and concomitant
suprarenal abdominal aortic aneurysms (AAAs)
Variable Control Suprarenal ﬁxation Infrarenal ﬁxation P
Max diameter, mm
Suprarenal 36.6 6 3.4 34.6 6 3.0 34.0 6 3.3 <.0001
Infrarenal 35.2 6 9.9 60.1 6 14.4 54.6 6 9.5 <.0001
Infrarenal
AAA volume, mL 72.6 6 43.1 209.3 6 116.3 150.6 6 55.8 <.0001
Neck length, mm 22.6 6 14.4 18.6 6 11.8 21.5 6 14.5 .31
Diameter at renals, mm 27.4 6 3.1 27.2 6 2.8 26.2 6 3.2 <.01
Distal renal to aortic bifurcation, mm 105.9 6 24.5 129.7 6 19.4 123.0 6 13.8 <.0001
Proximal neck to iAAA angle, 152.7 6 16.0 142.3 6 19.4 145.0 6 12.6 <.0005
Suprarenal AAA angle, 160.8 6 14.7 158.5 6 14.5 162.0 6 11.6 .23
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2.8 mm). The distance from the distal renal to the aortic
bifurcation was signiﬁcantly shorter and the proximal
neck to the iAAA angle was signiﬁcantly larger in the
control group. The suprarenal angle was not signiﬁcantly
different among the three groups.
Growth rates. Aortic growth rates were calculated for
the control, SR, and IR groups and are presented in
Table II. Patient follow-up averaged 33.0 6 18.8 months
(control, 34.0 6 20.2 months; SR, 34.2 6 18.0 months;
IR, 30.46 18.6 months; P ¼ .20). The sAAA growth rates
for the SR (0.6 6 1.1 mm/y) and IR (0.6 6 1.3 mm/y)
groups were similar (P > .05), whereas the growth rate for
the control group (1.2 6 1.5 mm/y; P < .05) was
signiﬁcantly higher. The iAAAs in the control group
enlarged (1.1 6 3.3 mm/y) during the study period,
whereas the patients undergoing EVAR (SR and IR)
showed evidence of iAAA shrinkage. The iAAA growth rate
and iAAA volume growth rate were not signiﬁcantly
different between the SR (2.1 6 5.4 mm/y and 12.06
34.0 mL/y) and IR (1.0 6 4.6 mm/y and 4.3 6
27.4 mL/y; P > .05) groups. The aortic growth at the
renals was similar for all groups (control, 0.6 6 1.4 mm/y;
SR, 1.0 6 1.7 mm/y; and IR, 1.0 6 1.5 mm/y; P ¼ .11).
Growth of sAAAs to $50 mm. Six of 217 patients
(2.8%) had sAAAs that grew to $50 mm at an average of
50.4 6 25.2 months. There was no statistical difference
in the frequency of growth of the sAAA to $50 mm
comparing patients who were treated with EVAR (two of
152 [1.3%]) with control patients (four of 64 [6.3%];
P ¼ .07). The incidence of growth of the sAAA to
$50 mm in EVAR-treated patients was similar with or
without SR (one of 90 [1.1%]) or IR (one of 62 [1.6%];
P > .99). A Kaplan-Meier survival curve shows the freedom
from sAAA growth to a size of $50 mm was not signiﬁ-
cantly different for patients undergoing EVAR vs controls
(P ¼ .061), and the freedom from sAAA growth to a size of
$50 mm at 48 months was 99.3% for EVAR-treated
patients and 95.2% for controls (Fig 2). The sAAA size
over time is presented in Fig 3. This demonstrates that the
patients whose sAAAs grew to $50 mm had variable
starting diameters of 32.3 to 46.7 mm, but all had elevatedgrowth rates, with a mean growth rate that was faster
(4.4 6 2.3 mm/y; range, 2.3-8.0 mm/y) compared with
the average growth rate for all patients in the study whose
sAAAs remained <50 mm (0.7 6 1.1 mm/y; P < .0001).
Initial sAAA size and growth to a size of $50 mm.
When sAAAs with an initial size of <40 mm were
compared with those with an initial size of $40 mm, the
larger sAAAs had a faster growth rate (1.4 6 2.1 vs
0.7 6 1.2 mm/y; P < .05) and a higher frequency of
sAAA growth to a size of $50 mm (three of 21 [14%] vs
three of 196 [1.5%]; P < .01).
DISCUSSION
This anatomic study looking at the fate of concomitant
sAAAs after treatment of iAAAs with EVAR demonstrates
that after EVAR, there is a low rate of growth of concom-
itant sAAAs to a size that may require intervention. This is
an important ﬁnding because it demonstrates that it is
appropriate to treat the iAAA and observe the sAAA and
that many patients will never require an intervention for
their sAAA.
Our data suggest that EVAR with or without SR does
not lead to faster sAAA growth. This is supported by
similar 48-month Kaplan-Meier curves showing freedom
from sAAA progression for EVAR-treated patients and
controls. Furthermore, the incidence of sAAA growth to
$50 mm and the sAAA growth rate is equal after EVAR
with devices with or without SR. It is interesting that there
is a trend toward improved freedom from sAAA growth to
$50 mm in our EVAR-treated patients going out 4 years
after EVAR (Fig 2) and that the sAAA growth rate was
signiﬁcantly higher for our control patients than with
EVAR-treated patients (Table II). The reason for this
ﬁnding is not clear; however, our data suggest that
EVAR with or without SR does not have deleterious effects
on a concomitant sAAA.
Patients with multiple AAAs often have many comor-
bidities that may lead to a limited life expectancy. Crawford
and Cohen reported 5-year survival of patients with
multiple aortic aneurysms was <50% for those treated
with various surgical approaches.1 A more recent series of
patients undergoing repair of type IV thoracoabdominal
Table II. Growth rates and follow-up in patients with infrarenal abdominal aortic aneurysms (iAAAs) concomitant
suprarenal abdominal aortic aneurysms (sAAAs)
Variable Control Suprarenal ﬁxation Infrarenal ﬁxation P
sAAA growth rate, mm/y 1.2 6 1.5 0.6 6 1.1 0.6 6 1.3 <.005
iAAA growth rate, mm/y 1.1 6 3.3 2.1 6 5.4 1.0 6 4.6 <.0001
iAAA volume growth rate, mL/y 4.0 6 12.3 12.0 6 34.0 4.3 6 27.4 <.0001
@ renals growth rate, mm/y 0.6 6 1.4 1.0 6 1.7 1.0 6 1.5 .11
Follow-up, months 34.0 6 20.2 34.2 6 18.0 30.4 6 18.6 .20
Fig 2. Kaplan-Meier analysis of freedom from suprarenal
abdominal aortic aneurysm (sAAA) growth to $50 mm in patients
undergoing endovascular aortic repair (EVAR) and in controls.
Fig 3. Suprarenal abdominal aortic aneurysm (sAAA) size over
time and growth rate in all study patients progressing to $50 mm.
C, Control; IR, infrarenal ﬁxation; SR, suprarenal ﬁxation.
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10-year survival of 36%.2 For patients with concomitant
iAAAs and sAAAs, the longevity of the aneurysm treatment
must be evaluated in relation to the longevity of the
patient. In our study, sAAA growth to a size of $50 mm
was only seen in 2.8% of patients, and the average time
for this to occur was 50.4 months. Many of these patients
have a limited life expectancy, and for those few patients
whose sAAAs go on to reach a size of $50 mm, there
may be a signiﬁcant period of time after EVAR before an
intervention is required for their sAAA. Many patients
will never require an intervention for the sAAA. However,
because of the small number of patients in our study with
follow-up >5 years, it is hard to draw conclusions about
the fate of these sAAAs in patients with a prolonged life
expectancy.
When we looked at patients whose initial sAAA diam-
eter was <40 mm vs those $40 mm, the larger aneurysms
had a growth rate that was twice as fast and a frequency of
growth to a size of $50 mm that was 9.3-fold higher than
the smaller aneurysms. However, sAAAs that eventually
went on to grow to a diameter of $50 mm had a wide
range of starting sizes, indicating that initial size alone isnot a good predictor of which sAAAs will grow to a size
requiring intervention.
To better understand what leads to sAAAs ultimately
reaching a size of $50 mm, we must also consider growth
rate. sAAAs reaching a size of$50 mm all had one common
feature, which was a growth rate that was signiﬁcantly higher
than the average sAAA growth rate. This demonstrates that
some sAAAs have intrinsically higher growth rates for
reasons that are unclear and that these higher growth rates
are not necessarily correlated with size. Ultimately, growth
rate is the factor driving an sAAA to reach a size of
$50 mm, and identifying patients with an sAAA initial size
of $40 mm selects out patients whose aneurysms have
already demonstrated growth potential and are therefore
at higher risk to continue to grow in the future. We must
JOURNAL OF VASCULAR SURGERY
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have an sAAA sized <40 mm that also have an elevated
growth rate. These patients are earlier in their disease
process, and their aneurysms are small because they have
not had enough time to grow. These patients are also at
risk of ultimately reaching a size of $50 mm and may be
harder to identify initially.
On the basis of these data, we recommend that for
patients with an iAAA requiring intervention and a concom-
itant sAAA of <50 mm, it is appropriate to treat the iAAA
with EVAR, when anatomically suitable, and monitor the
sAAA. Stent grafts with SR do not appear to affect the
growth rate of sAAAs, and devices with SR may be used
when anatomically appropriate. For patients with sAAAs
with initial sizes of <40 mm, routine EVAR follow-up
imaging is sufﬁcient. For patients with sAAAs with initial
sizes of $40 mm, we recommend that more intensive
follow-up be considered because these patients generally
have a higher growth rate and are closer to a size where
repair should be considered. This does not necessarily
mean more frequent CT imaging. Extra care should be
taken so that these patients are not lost to follow-up, and
imaging needs to accurately size the suprarenal aorta.
Duplex ultrasound imaging has been advocated as an
alternative to CTA that can minimize radiation exposure
and identify complications requiring intervention.3-7 For
some patients with a favorable body habitus, duplex ultra-
sound imaging may be sufﬁcient to monitor the sAAA and
also the stent grafted infrarenal aorta. For larger patients,
CT may need to be used to get an accurate suprarenal
size; however, a noncontrast CT will accurately measure
the size of the suprarenal aorta and can be used in patients
with renal failure.
Finally, for patients whose sAAA initial size approaches
50 mm, we recommend using a device with IR to treat the
iAAA. This recommendation is not based on a concern that
the SR device will increase the rate of growth of the sAAA,
because our data would not support this. Rather, these
sAAAs are likely at the highest risk of requiring intervention
in the future, and the absence of hardware in the suprarenal
aorta will simplify any subsequent operations or endovascu-
lar procedures to treat the suprarenal aorta.
Although the number of patients and the methodology
of data collection are strengths of this study that allow us to
be conﬁdent in our conclusions, there are some limitations
that must be pointed out. First, this study is limited because
it is an anatomic study without any demographic informa-
tion on the patients. One would predict that certain patient
characteristics, such as smoking status, hypertension, dysli-
pidemia, sex, genetic disorders, vasculitis, or family history
of aneurysms, might be helpful in predicting risk of growth
of a concomitant sAAA; however, our study does not
address the role that these factors play in sAAA growth.8-11
Therefore, our study does not deﬁne how these factors
should play into the decision-making process in patients
with concomitant sAAAs. The rate of iAAA growth
in our patients was less than what has been previously
reported, and the cause of this ﬁnding is unclear.12-15However, it is worth noting that previous studies looking
at the rate of AAA expansion were done in a different era
when differences in patient factors, such as tobacco use,
and management of comorbidities, such as hypertension
and dyslipidemia, might have affected AAA growth rates.
However, without demographic data on our patient pop-
ulation, this is only a hypothesis.
Second, we do not have outcome data on the patients
after their EVAR procedures. It is possible that patients
with iAAAs and concomitant sAAAs represent a subset of
patients with more severe vascular disease, thus altering
the risk-beneﬁt proﬁle for treating these patients with
EVAR, but our data cannot address this hypothesis. It is,
however, unlikely that these patients are at higher risk of
device-related complications, such as endoleaks or aneu-
rysm sac expansion due to the concomitant sAAA, because
the iAAAs and sAAAs included in the study were truly two
separate foci of aneurysmal disease in the aorta rather than
a diffusely aneurysmal aorta including both the infrarenal
and suprarenal segments. This is evident by the fact that
the average infrarenal neck length for patients undergoing
EVAR was 18.6 to 22.5 mm, and the average aortic size at
the renal arteries was 26.2 to 27.2 mm. The presence of the
sAAA would not affect the suitability of the patient for
treatment with EVAR based on any of the commercial
device instructions for use, and the presence of the sAAA
should not predispose the patients to device-related
complications after EVAR to treat the iAAA.
There was some mild increase in aortic diameter over
time at the level of the renal arteries. However, similar dila-
tion aortic neck dilation has been reported in patients
undergoing EVAR without the presence of an sAAA, and
this has not been shown to affect outcomes after
EVAR.16-19 Therefore, we would recommend using the
same criteria to treat an iAAA with EVAR regardless of
whether or not a concomitant sAAA is present.
CONCLUSIONS
Our study demonstrates that patients with iAAAs and
concomitant sAAAs can be managed with EVAR to treat
the iAAA and that the sAAA can be monitored with serial
imaging. Only a minority of patients with sAAAs of
<50 mm will go on to require surgical intervention for
the sAAA. Stent grafts with SR do not appear to affect
sAAA growth rate and may be appropriate for use in these
patients.
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interesting that the rate of expansion for your suprarenal aortic
aneurysms is lower than reported rates for infrarenal aneurysms.
Is there information about how many patients were on statins or
on the rate of hypertension? Were these patients more carefully
managed medically? Or perhaps the visceral segment is just more
stable?
Dr Benjamin J. Herdrich. I think based on this study it is
really unclear. We did not have demographic data on these
patients, so we don’t know what percentage were on statins or
what their blood pressure control was. We just had radiographic
data, such as the measurements of their aortas over time and
whether or not they had stent grafts and suprarenal ﬁxation. So
it is really hard to draw conclusions from these data to answer
your question.
As to why the suprarenal aorta growth rates were less than
reported growth rates in the infrarenal aorta, I would just be
speculating. I will say it is interesting that the growth rates in
our endovascular aortic repair (EVAR) patients were signiﬁcantly
less than the growth rates in our control patients. And while I
wouldn’t go out on a limb and say that this proves that EVAR
can promote remodeling of the suprarenal aorta, it is kind of an
interesting ﬁnding.
Dr Tara Mastracci (Cleveland, Ohio). I am interested to
know if you have any data on the rate of reintervention for the
infrarenal devices that were in these patients where you implanted
them with a concomitant aneurysm above. Speciﬁcally, did you
notice there was a rate of failure for the devices when you
implanted with an aneurysm so close?Dr Herdrich. This was primarily an anatomic study and not
designed to look at additional outcome measures. I did present
data showing that overall, for patients in both of our EVAR
groups, the mean infrarenal aortic aneurysm size and volume
decreased in both of those groups. Now, that wasn’t true for every
patient. Some of those patients did go on to have increasing aortic
size, and we really don’t have data on the outcomes of that. But
overall, I think that the procedures seemed to have been successful
given the fact that the infrarenal aneurysms shrunk.
Dr Mark Farber (Chapel Hill, NC). It appears these aren’t
necessarily your patients, these are M2S data sets that you are look-
ing atddo you have any data on what the size of the suprarenal
and superior mesenteric artery diameter is vs the infrarenal diam-
eter? In our experience, rarely do we ﬁnd patients with normal
suprarenal aortas and infrarenal aortic aneurysms that are
completely isolated, as they generally have a dilated segment.
Because we are getting ready to embark on fenestrated grafts
in the United States and we know from the Cleveland Clinic’s
experience that if you place grafts in already dilated or preaneurys-
mal segments they tend to fail at a much higher rate, I am surprised
that you haven’t looked at failure rates of the infrarenal devices
because I think it would be an interesting ﬁnding if you could
look into that and let us know what those diameters are if you
have that data.
Dr Herdrich. We just don’t have the data on the failure rates
because this was an anatomic study. As for the diameters, our
average diameters of our infrarenal aortic aneurysms for our control,
suprarenal, and infrarenal groups were 3.5 cm, 6 cm, and, I believe,
5.4 cm. Now, the diameter at the renals, or actually 1 mm below the
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our suprarenal aortic sizes were 34 to 36 mm. So there is some
infrarenal aortic neck in all of these patients. The average infrarenal
neck length was 18 to 22 mm, depending on the group. Now, in
some of the patients, the neck was only a couple millimeters;
however, in many patients, it was a sizable neck.
Dr Frederick Beavers (Washington, D.C.). I’d like to convert
this over to a little bit of just everyday practical medicine on two
points. Number one, the majority of us probably don’t use M2S
as an imaging modality. It costs money, and insurance doesn’t
cover it in a lot of locations. So we rely on our community radiol-
ogists to read the computed tomography (CT) scans for us, unless
we read them ourselves. Some reported literature says there is
interobserver error. And usually, if we rely on our community radi-
ologists, we won’t get the same radiologist reading this CT scan.
So how does that play into the data that you presented?
The second question is: There is a recent report out that in CT
scans in adolescents, there is an increased incidence of brain cancer
and leukemia. Once the lay public gets a hold of these data, I am
concerned that they may not want to follow these protocols that
we are putting forth. Do you have any data that magnetic reso-
nance (MR) technology is as sensitive as the CT scan results that
you’ve reported?Dr Herdrich. With regard to places that may not have access
to M2S, I think generally the measurements that we have pre-
sented here are fairly basic measurements that can be made on
a routine axial CT angiography. So I don’t know that you need
M2S to make these measurements, but the M2S database was
a good source to get a large number of patients that had these
concomitant aneurysms. I think out in the community, people
will still be able to use these data and make these measurements.
Dr Beavers. How about correlating the ability of MR tech-
nology to be equivalent to CT?
Dr Herdrich. Well, I think that whatever test you use to
measure the aortic size that as long as you get an accurate aortic
size that that is sufﬁcient. Now, with MR technology the question
is, do you get an accurate aortic size? And I think that there are
many factors that go into itdwhat type of stent graft is being
used, what is the material of the stent graft, what is the experience
with MR at your institutiondso you have to take all those things
into consideration.
We use ultrasound in some of these patients to monitor them,
and that is another alternative. In patients who are thin and you
can get good views of the aorta, they don’t necessarily need
a CT scan every 6 months or every year. You could consider using
ultrasound in those patients.
